MA44670B1 - Protéines de liaison trispécifiques et/ou trivalentes - Google Patents
Protéines de liaison trispécifiques et/ou trivalentesInfo
- Publication number
- MA44670B1 MA44670B1 MA44670A MA44670A MA44670B1 MA 44670 B1 MA44670 B1 MA 44670B1 MA 44670 A MA44670 A MA 44670A MA 44670 A MA44670 A MA 44670A MA 44670 B1 MA44670 B1 MA 44670B1
- Authority
- MA
- Morocco
- Prior art keywords
- trispecific
- binding proteins
- binding
- trivalent binding
- proteins
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 5
- 108091008324 binding proteins Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000021127 protein binding proteins Human genes 0.000 abstract 1
- 108091011138 protein binding proteins Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
L'invention concerne des compositions comprenant des protéines de liaison trispecifiques et/ou trivalentes comprenant quatre chaînes polypeptidiques qui forment trois sites de liaison à l'antigène qui se lient spécifiquement à une ou plusieurs protéines cibles, une première paire de polypeptides qui forme la protéine de liaison possédant des domaines variables doubles ayant une orientation croisée et une seconde paire de polypeptides qui forme la protéine de liaison possédant un domaine variable unique. L'invention concerne également des procédés de production de protéines de liaison trispécifiques et/ou trivalentes et des utilisations de telles protéines de liaison.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305298 | 2017-03-17 | ||
PCT/US2017/027488 WO2017180913A2 (fr) | 2016-04-13 | 2017-04-13 | Protéines de liaison trispécifiques et/ou trivalentes |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44670A MA44670A (fr) | 2019-02-20 |
MA44670B1 true MA44670B1 (fr) | 2023-11-30 |
Family
ID=58464471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44670A MA44670B1 (fr) | 2017-03-17 | 2017-04-13 | Protéines de liaison trispécifiques et/ou trivalentes |
Country Status (23)
Country | Link |
---|---|
US (2) | US10882922B2 (fr) |
EP (1) | EP3443006B1 (fr) |
JP (1) | JP7195929B2 (fr) |
KR (1) | KR20180134378A (fr) |
CN (1) | CN109476732B (fr) |
AU (1) | AU2017248671B2 (fr) |
BR (1) | BR112018070998A2 (fr) |
CA (1) | CA3020633A1 (fr) |
CL (1) | CL2018002883A1 (fr) |
CO (1) | CO2018012107A2 (fr) |
CR (1) | CR20180539A (fr) |
DO (1) | DOP2018000225A (fr) |
EA (1) | EA201892312A1 (fr) |
IL (1) | IL262241B2 (fr) |
MA (1) | MA44670B1 (fr) |
MX (1) | MX2018012566A (fr) |
PE (1) | PE20190128A1 (fr) |
PH (1) | PH12018502182A1 (fr) |
PT (1) | PT3443006T (fr) |
SG (1) | SG11201808911SA (fr) |
TW (1) | TWI788286B (fr) |
UY (1) | UY37206A (fr) |
WO (1) | WO2017180913A2 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2016116626A1 (fr) * | 2015-01-23 | 2016-07-28 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
BR112018008011A2 (pt) | 2015-10-25 | 2018-10-30 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv |
ES2960329T3 (es) | 2016-04-13 | 2024-03-04 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes |
JP7195929B2 (ja) | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および/または三価結合タンパク質 |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子 |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
WO2019074973A2 (fr) | 2017-10-10 | 2019-04-18 | Sanofi | Anticorps anti-cd38 et procédés d'utilisation |
US20210324108A1 (en) * | 2017-11-01 | 2021-10-21 | Hoffmann-La Roche Inc. | Bispecific 2+1 contorsbodies |
AU2018371114A1 (en) * | 2017-11-21 | 2020-05-07 | Innate Pharma | Multispecific antigen binding proteins |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
CN111448217A (zh) | 2017-12-22 | 2020-07-24 | 阿根思公司 | 双特异性抗原结合构建体 |
BR112020013325A2 (pt) | 2018-01-12 | 2020-12-01 | Genzyme Corporation | métodos para quantificação de polipeptídeos |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
WO2019160904A1 (fr) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Domaines variants de liaison à cd3 et leur utilisation en polythérapies pour le traitement d'une maladie |
CN112119099A (zh) * | 2018-03-02 | 2020-12-22 | Cdr-生物科技股份有限公司 | 三特异性抗原结合蛋白 |
CN111836644B (zh) * | 2018-03-08 | 2024-07-23 | 凡恩世制药(北京)有限公司 | 抗密蛋白18.2抗体及其用途 |
EP3765516A2 (fr) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
EP3774918A4 (fr) * | 2018-03-27 | 2022-04-06 | Systimmune, Inc. | Procédés de production et d'utilisation de protéines de contrôle de guidage et de navigation |
US10640576B2 (en) * | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
CA3097605A1 (fr) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Constructions d'anticorps trispecifiques trivalents |
CA3109513A1 (fr) * | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-fc epsilon-r1 alpha (fcer1a), molecules bispecifiques de liaison a l'antigene se liant au fcer1a et au cd3, et utilisations associees |
AU2019357467A1 (en) * | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
CN111153988B (zh) * | 2018-11-08 | 2022-11-04 | 中国科学院上海巴斯德研究所 | 广谱抗肠道病毒d68型的中和性单克隆抗体 |
AU2019412561A1 (en) * | 2018-12-24 | 2021-08-12 | Sanofi | Multispecific binding proteins with mutant Fab domains |
EP3674316A1 (fr) | 2018-12-24 | 2020-07-01 | Sanofi | Protéines de liaison multispécifiques avec des domaines fab mutants |
CA3124770A1 (fr) | 2018-12-24 | 2020-07-02 | Sanofi | Nouvelles proteines de liaison multi-specifiques a base de pseudofab |
CN113646334A (zh) * | 2019-02-20 | 2021-11-12 | 国家儿童医院研究所 | 癌症靶向的、病毒编码的、可调节的t细胞(catvert)或nk细胞(catvern)接头 |
TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
AU2020272839A1 (en) * | 2019-04-09 | 2021-12-02 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
CN112111012B (zh) * | 2019-06-20 | 2023-07-04 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
CA3147044A1 (fr) * | 2019-07-11 | 2021-01-14 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents qui interferent avec la signalisation du recepteur de lymphopoietine stromale thymique (tslp) |
US20220112258A1 (en) * | 2019-07-25 | 2022-04-14 | I-Mab Biopharma Us Limited | Bifunctional molecules with il-7 activity |
JP2022553716A (ja) | 2019-10-25 | 2022-12-26 | サノフイ | 多特異性結合タンパク質において鎖誤対合を分析する方法 |
JP2022553830A (ja) * | 2019-11-05 | 2022-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | N末端scFv多重特異性結合分子 |
MX2022010549A (es) | 2020-02-26 | 2022-11-16 | Biograph 55 Inc | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. |
TW202146463A (zh) | 2020-03-05 | 2021-12-16 | 法商賽諾菲公司 | 蛋白酶加工的分子 |
JP2023519699A (ja) * | 2020-03-30 | 2023-05-12 | サノフイ | スプリットch2ドメイン |
CR20220627A (es) * | 2020-06-23 | 2023-02-17 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se derigen a her2 |
WO2022036495A1 (fr) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations |
MX2023003214A (es) * | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
CA3216005A1 (fr) | 2021-05-27 | 2022-12-01 | Jochen Beninga | Variant fc a affinite amelioree vis-a-vis de recepteurs fc et stabilite thermique amelioree |
CN118317979A (zh) * | 2021-09-29 | 2024-07-09 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
KR20240099224A (ko) * | 2021-09-29 | 2024-06-28 | 모덱스 테라퓨틱스, 인크. | 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 이의 사용 방법 |
CN118076387A (zh) * | 2021-10-08 | 2024-05-24 | 艾贝乐医药科技有限公司 | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 |
WO2023155844A1 (fr) * | 2022-02-16 | 2023-08-24 | 上海优替济生生物医药有限公司 | Anticorps anti-cd40 à maturation d'affinité |
AU2023228391A1 (en) * | 2022-03-03 | 2024-09-19 | Pfizer Inc. | Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof |
US20240228650A9 (en) | 2022-05-06 | 2024-07-11 | Ichnos Sciences SA | CD3/BCMA/CD38 Trispecific Antibodies |
WO2023227790A1 (fr) | 2022-05-27 | 2023-11-30 | Sanofi | Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc |
WO2023246911A1 (fr) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | Molécule polypeptidique bispécifique à base de récepteur de lymphocytes t et son utilisation |
WO2024027828A1 (fr) * | 2022-08-05 | 2024-02-08 | Chimagen Biosciences, Ltd | Anticorps multi-spécifiques ciblant un antigène tumoral dimérisable et un antigène immunostimulant |
WO2024131731A1 (fr) * | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | Protéine de liaison multi-spécifique à liaison série fab-fab " kappa/lambda ", sa préparation et son utilisation |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338518C (fr) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Heteroconjugues d'anticorps pour tuer les cellules infectees par le vih |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
KR100927261B1 (ko) * | 2001-01-17 | 2009-11-18 | 트루비온 파마슈티칼스, 인코포레이티드 | 결합 도메인-면역글로불린 융합 단백질 |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
JP5068072B2 (ja) | 2003-06-27 | 2012-11-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 連結ペプチドを含む改変された結合分子 |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
EP2050764A1 (fr) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
EP2297209A4 (fr) | 2008-06-03 | 2012-08-01 | Abbott Lab | Immunoglobulines à deux domaines variables et leurs utilisations |
WO2011038290A2 (fr) | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Anticorps neutralisants dirigés contre le vih-1 et utilisation associée |
DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2012154312A1 (fr) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps neutralisants anti-vih-1 et leur utilisation |
JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
SI2710033T1 (sl) | 2011-05-17 | 2021-05-31 | The Rockefeller University | Virus humane imunske pomanjkljivosti nevtralizirajoča protitelesa in metode njihove uporabe |
RU2624046C2 (ru) | 2011-11-07 | 2017-06-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Gp41-нейтрализующие антитела и их применение |
AU2012347453B2 (en) | 2011-12-08 | 2017-11-23 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
WO2013163427A1 (fr) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps pour traiter les infections par le vih-1 |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
IN2015MN00139A (fr) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
WO2014116846A2 (fr) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Procédés et compositions pour moduler une réponse immunitaire |
KR102282761B1 (ko) | 2013-02-26 | 2021-07-30 | 로슈 글리카트 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
AU2014227664A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Inc. | Dual specific binding proteins directed against TNFalpha |
AU2014343636A1 (en) | 2013-11-04 | 2016-06-02 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
US9822186B2 (en) * | 2014-03-28 | 2017-11-21 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
US10961506B2 (en) | 2014-09-04 | 2021-03-30 | Stemcell Technologies Inc. | Soluble antibody complexes for T cell or NK cell activation and expansion |
WO2016116626A1 (fr) | 2015-01-23 | 2016-07-28 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
US10654943B2 (en) | 2015-06-02 | 2020-05-19 | The Rockefeller University | Tri-specific antibodies for HIV therapy |
US10738099B2 (en) | 2015-09-22 | 2020-08-11 | The Trustees Of The University Of Pennsylvania | Method of redirecting T cells to treat HIV infection |
BR112018008011A2 (pt) | 2015-10-25 | 2018-10-30 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv |
CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞 |
MA44077A (fr) | 2015-12-15 | 2021-05-05 | Gilead Sciences Inc | Anticorps neutralisants le virus de l'immunodéficience humaine |
JP7195929B2 (ja) | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および/または三価結合タンパク質 |
EP3575319A4 (fr) | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | Molécule bifonctionnelle et son utilisation |
JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン2に対する特異性を有する多特異性結合性分子 |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
WO2019074973A2 (fr) | 2017-10-10 | 2019-04-18 | Sanofi | Anticorps anti-cd38 et procédés d'utilisation |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2017
- 2017-04-13 JP JP2018554100A patent/JP7195929B2/ja active Active
- 2017-04-13 SG SG11201808911SA patent/SG11201808911SA/en unknown
- 2017-04-13 IL IL262241A patent/IL262241B2/en unknown
- 2017-04-13 WO PCT/US2017/027488 patent/WO2017180913A2/fr active Application Filing
- 2017-04-13 MA MA44670A patent/MA44670B1/fr unknown
- 2017-04-13 TW TW106112360A patent/TWI788286B/zh active
- 2017-04-13 EA EA201892312A patent/EA201892312A1/ru unknown
- 2017-04-13 CA CA3020633A patent/CA3020633A1/fr active Pending
- 2017-04-13 KR KR1020187032530A patent/KR20180134378A/ko not_active IP Right Cessation
- 2017-04-13 AU AU2017248671A patent/AU2017248671B2/en active Active
- 2017-04-13 PT PT177322633T patent/PT3443006T/pt unknown
- 2017-04-13 PE PE2018001987A patent/PE20190128A1/es unknown
- 2017-04-13 CN CN201780036515.9A patent/CN109476732B/zh active Active
- 2017-04-13 BR BR112018070998-0A patent/BR112018070998A2/pt unknown
- 2017-04-13 CR CR20180539A patent/CR20180539A/es unknown
- 2017-04-13 US US15/487,243 patent/US10882922B2/en active Active
- 2017-04-13 MX MX2018012566A patent/MX2018012566A/es unknown
- 2017-04-13 EP EP17732263.3A patent/EP3443006B1/fr active Active
- 2017-04-18 UY UY0001037206A patent/UY37206A/es not_active Application Discontinuation
-
2018
- 2018-10-10 CL CL2018002883A patent/CL2018002883A1/es unknown
- 2018-10-11 PH PH12018502182A patent/PH12018502182A1/en unknown
- 2018-10-12 DO DO2018000225A patent/DOP2018000225A/es unknown
- 2018-11-09 CO CONC2018/0012107A patent/CO2018012107A2/es unknown
-
2020
- 2020-11-16 US US17/099,439 patent/US11192960B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44670B1 (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
MA35051B1 (fr) | Protéines de liaison à des anticorps-like à double région variable ayant une orientation croisée de région de liaison | |
MA42641A1 (fr) | Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih | |
MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
WO2018134235A8 (fr) | Liants d'albumine sérique améliorés | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
MX2022007636A (es) | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. | |
MX2022011935A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
WO2020039321A8 (fr) | Anticorps anti-gdf15, compositions et procédés d'utilisation | |
MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
EP4374916A3 (fr) | Nouvelle forme d'il33, formes mutantes d'il33, anticorps, dosages biologiques et procédés d'utilisation de ceux-ci | |
MX2019003225A (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados. | |
EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
WO2019060750A3 (fr) | Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie | |
MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
WO2019195623A3 (fr) | Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes | |
MX2020000583A (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados. | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
MX2021012386A (es) | Proteínas de union triespecíficas, métodos y usos de las mismas. | |
MX2022006881A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
WO2019094533A8 (fr) | Agents de liaison à angptl8 et leurs méthodes d'utilisation | |
WO2021024133A3 (fr) | Compositions biopharmaceutiques et procédés associés | |
MX2022016322A (es) | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413. |